维布医药(Veeva)
VEEV
310.36
-2.67
-0.85%
维布医药(Veeva)
US · VEEV
#470 按市值排名
上市于 1970
310.36
-2.67
-0.85%
实时 - 追踪5344个代码 - 心跳于185秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了5家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 90.78% +0.09pp
- 机构数量
- 1,319 -5
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund72.02%
Hedge Fund8.80%
Individual/Insider8.31%
Public Company3.42%
Government Pension Fund2.36%
Private Company1.44%
Sovereign Wealth Fund0.91%
Family Office/Trust0.69%
VC/PE Fund0.64%
Other1.41%
主要股东 截至 2026-06-30
BlackRock
7.94% · 12.86M 股
Peter Gassner
7.58% · 12.27M 股
Vanguard Capital Management, LLC
6.51% · 10.53M 股
Vanguard Portfolio Management, LLC
4.58% · 7.41M 股
State Street Global Advisors
4.14% · 6.71M 股
T. Rowe Price Group, Inc.
3.83% · 6.21M 股
Principal Global Investors, LLC
3.09% · 5.00M 股
AllianceBernstein
3.03% · 4.91M 股
Geode Capital Management, LLC
2.78% · 4.51M 股
The Linonia Partnership LP
2.72% · 4.41M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 29次买入 · 18次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Peter Gassner | Chief Executive Officer | 7.58% |
| Gordon Ritter | Independent Chairperson | 0.42% |
| Matthew Wallach | Independent Director | 0.22% |
| Eleni Zuppas | Chief Marketing Officer | 0.02% |
| Thomas Schwenger | President | 0.01% |
| Paul Sekhri | Independent Director | 0.01% |
| Mark Carges | Independent Director | 0.01% |
| Brian Van Wagener | Chief Financial Officer | 0.01% |
| Jonathan Faddis | Senior Vice President | 0.01% |
| Dan Rizzo | EVP of Sales, Consulting & Services | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-04 | Thomas Schwenger | President | Intent to Sell (Form 144) | -132,751 | $279.73 |
| 2026-10-01 | Jonathan Faddis | Senior Vice President | Derivative Exercise and Sale | -1,636 | $281.93 |
| 2026-10-01 | Dan Rizzo | EVP of Sales, Consulting & Services | Derivative Exercise and Sale | -1,672 | $276.53–281.93 |
| 2026-10-01 | Dan Rizzo | EVP of Sales, Consulting & Services | Open Market Disposition | -4,023 | $276.21–276.53 |
| 2026-09-30 | Eleni Zuppas | Chief Marketing Officer | Derivative Exercise and Sale | -1,110 | $281.93 |
| 2026-09-30 | Eleni Zuppas | Chief Marketing Officer | Derivative Exercise and Retained | +1,071 | -- |
| 2026-09-30 | Thomas Schwenger | President | Derivative Exercise and Sale | -1,272 | $281.93 |
| 2026-09-30 | Thomas Schwenger | President | Derivative Exercise and Retained | +1,635 | -- |
| 2026-09-30 | Brian Van Wagener | Chief Financial Officer | Derivative Exercise and Sale | -705 | $281.93 |
| 2026-09-30 | Brian Van Wagener | Chief Financial Officer | Derivative Exercise and Retained | +931 | -- |
| 2026-09-30 | Vipin Kondath | Principal Accounting Officer | Derivative Exercise and Sale | -61 | $281.93 |
| 2026-09-30 | Vipin Kondath | Principal Accounting Officer | Derivative Exercise and Retained | +107 | -- |
| 2026-09-17 | Dan Rizzo | EVP of Sales, Consulting & Services | Initial Statement of Beneficial | 0 | -- |
| 2026-09-13 | Thomas Schwenger | President | Automatic Disposition | -1,000 | $265.20 |
| 2026-09-08 | Priscilla Hung | Independent Director | Open Market Disposition | -750 | $261.04 |
| 2026-08-31 | Paul Sekhri | Independent Director | Derivative Exercise and Retained | +460 | -- |
| 2026-08-31 | Gordon Ritter | Independent Chairperson | Other Acquisition | +15,585 | -- |
| 2026-08-31 | Gordon Ritter | Independent Chairperson | Derivative Exercise and Retained | +541 | -- |
| 2026-08-31 | Marshall Mohr | Independent Director | Derivative Exercise and Retained | +525 | -- |
| 2026-08-31 | Mark Carges | Independent Director | Derivative Exercise and Retained | +493 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:28 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
维布医药(Veeva) 讨论区 0 条评论